Prospects for therapeutic tolerance in humans

Current Opinion in Rheumatology

Volumn 26, Issue 2, 2014, Pages 219-227

  Baker, Kenneth F ^a   Isaacs, John D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

autoimmune; immune tolerance; regulatory T cell; therapeutic tolerance; therapy

Indexed keywords

ALLOGRAFTS; ANIMALS; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; CELL- AND TISSUE-BASED THERAPY; GRAFT SURVIVAL; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; MICROBIOTA; T-LYMPHOCYTES; TRANSLATIONAL MEDICAL RESEARCH; TRANSPLANTATION CHIMERA; TRANSPLANTATION IMMUNOLOGY;

EID: 84894040362     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000029     Document Type: Review

References (74)

1. Owen RD. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945; 102:400-401
2. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance to foreign cells. Nature 1953; 172:603-606
3. Issa F, Wood KJ. Translating tolerogenic therapies to the clinic: Where do we stand? Front Immunol 2012; 3:254
4. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant 2012; 12:1133-1145
5. Leventhal J, Abecassis M, Miller J, et al. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: Durable chimerism predicts outcome. Transplantation 2013; 95:169-176
6. Schneeberger S, Gorantla VS, Brandacher G, et al. Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg 2013; 257:345-351
7. Burr SP, Dazzi F, Garden OA. Mesenchymal stromal cells and regulatory T cells: The Ying and Yang of peripheral tolerance? Immunol Cell Biol 2013; 91:12-18
8. Hanley PJ, Mei Z, da GracaCabreira-Hansen M, et al. Manufacturing mesenchymal stromal cells for phase I clinical trials. Cytotherapy 2013; 15:416-422
9. Melief SM, Zwaginga JJ, Fibbe WE, Roelofs H. Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med 2013; 2:455-463
10. Davies LC, Lö nnies H, Locke M, et al. Oral mucosal progenitor cells are potently immunosuppressive in a dose-independent manner. Stem Cells Dev 2012; 21:1478-1487
11. Karlsson H, Erkers T, Nava S, et al. Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro. Clin Exp Immunol 2012; 167:543-555
12. Bernardo ME, Fibbe WE. Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann N Y Acad Sci 2012; 1266:107-117
13. Ra JC, Kang SK, Shin IS, et al. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med 2011; 9:181
14. Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: Results of a phase I study. Gut 2010; 59:1662-1669
15. Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: A phase II clinical trial. Dis Colon Rectum 2009; 52:79-86
16. Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrowderived mesenchymal stromal cells in the treatment of fistulating Crohn's disease. Gut 2011; 60:788-798
17. Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An openlabel phase 2a proof-of-concept study. Lancet Neurol 2012; 11:150-156
18. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010; 67:1187-1194
19. Sun L, Akiyama K, Zhang H, et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009; 27:1421-1432
20. Rubio R, Gutierrez-Aranda I, Sá ez-Castillo AI, et al. The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development. Oncogene 2013; 32:4970-4980
21. Patel SA, Meyer JR, Greco SJ, et al. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: Role of mesenchymal stem cell-derived TGF-beta. J Immunol 2010; 184:5885-5894
22. von Bahr L, Batsis I, Moll G, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-Term engraftment and no ectopic tissue formation. Stem Cells 2012; 30:1575-1578
23. Sagoo P, Lombardi G, Lechler RI. Relevance of regulatory T cell promotion of donor-specific tolerance in solid organ transplantation. Front Immunol 2012; 3:184
24. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 2011; 117:1061-1070
25. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117:3921-3928
26. Schmidl C, Hansmann L, Andreesen R, et al. Epigenetic reprogramming of the RORC locus during in vitro expansion is a distinctive feature of human memory but not nai?ve Treg. Eur J Immunol 2011; 41:1491-1498
27. Gravano DM, Vignali DA. The battle against immunopathology: Infectious tolerance mediated by regulatory T cells. Cell Mol Life Sci 2012; 69:1997-2008
28. Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011; 470:548-553
29. Zhang X, Huang H, Han S, et al. Alemtuzumab induction in renal transplantation: A meta-Analysis and systemic review. Transpl Immunol 2012; 27:63-68
30. Calne R, Watson CJ. Some observations on prope tolerance. Curr Opin Organ Transplant 2011; 16:353-358
31. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012; 380:1819-1828
32. Aranha AA, Amer S, Reda ES, et al. Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: A review. Endocr Pract 2013; 19:821-828
33. Daifotis AG, Koenig S, Chatenoud L, Herold KC. Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol 2013; 149:268-278
34. Penaranda C, Tang Q, Bluestone JA. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol 2011; 187:2015-2022
35. Hivroz C, Chemin K, Tourret M, Bohineust A. Crosstalk between T lymphocytes and dendritic cells. Crit Rev Immunol 2012; 32:139-155
36. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and coinhibition. Nat Rev Immunol 2013; 13:227-242
37. Sandborn WJ, Colombel JF, Sands BE, et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012; 143:62-69
38. Viglietta V, Bourcier K, Buckle GJ, et al. CTLA4Ig treatment in patients with multiple sclerosis: An open-label, phase 1 clinical trial. Neurology 2008; 71:917-924
39. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with nonlife-Threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62:3077-3087
40. Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. Lancet 2011; 378:412-419
41. Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: A clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010; 69:510-516
42. Isaacs JD. The changing face of rheumatoid arthritis: Sustained remission for all? Nat Rev Immunol 2010; 10:605-611
43. Wiendl H, Gross CC. Modulation of IL-2Ra with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol 2013; 9:394-404
44. Wuest SC, Edwan JH, Martin JF, et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med 2011; 17:604-609
45. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-Targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103:5941-5946
46. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013; 38:13-25
47. Goudy K, Aydin D, Barzaghi F, et al. Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clin Immunol 2013; 146:248-261
48. Saadoun D, Rosenzwajg M, Joly F, et al.Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011; 365:2067-2077
49. Greenberger PA, Ditto AM. Chapter 24: Anaphylaxis. Allergy Asthma Proc 2012; 33 (Suppl 1):S80-S83
50. Fujita H, Soyka MB, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy 2012; 2:2
51. Smits HH. B cells in allergic diseases: Bad or better? Autoimmunity 2012; 45:415-426
52. Kim EH, Bird JA, Kulis M, et al. Sublingual immunotherapy for peanut allergy: Clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 2011; 127:640-646
53. Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 2011; 127:654-660
54. Fuentes-Aparicio V, Alonso-Lebrero E, Zapatero L, et al. Oral immunotherapy in hen's egg-Allergic children increases a hypo-proliferative subset of CD4T cells that could constitute a marker of tolerance achievement. Pediatr Allergy Immunol 2012; 23:648-653
55. Reveille JD. Genetic studies in the rheumatic diseases: Present status and implications for the future. J Rheumatol Suppl 2005; 72:10-13
56. Proal AD, Albert PJ, Marshall TG. The human microbiome and autoimmunity. Curr Opin Rheumatol 2013; 25:234-240
57. Atarashi K, Honda K. Microbiota in autoimmunity and tolerance. Curr Opin Immunol 2011; 23:761-768
58. Wu HJ, Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T Helper 17 Cells. Immunity 2010; 32:815-827
59. Arvikar SL, Collier DS, Fisher MC, et al. Clinical correlations with Porphyromonas gingivalis antibody responses in patients with early rheumatoid arthritis. Arthritis Res Ther 2013; 15:R109
60. Yeoh N, Burton JP, Suppiah P, et al. The role of the microbiome in rheumatic diseases. Curr Rheumatol Rep 2013; 15:314
61. Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011; 331:337-341
62. Lathrop SK, Bloom SM, Rao SM, et al. Peripheral education of the immune system by colonic commensal microbiota. Nature 2011; 478:250-254
63. Kim SV, Xiang WV, Kwak C, et al. GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science 2013; 340:1456-1459
64. Smith CJ, Sayles H, Mikuls TR, Michaud K. Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: Prescribing patterns, patient-level determinants of use, and patient-reported side effects. Arthritis Res Ther 2011; 13:R168
65. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-Analysis. Am J Gastroenterol 2011; 106:661-673
66. Smits LP, Bouter KE, de Vos WM, et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013; 145:946-953
67. Vrieze A, de Groot PF, Kootte RS, et al. Fecal transplant: A safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease? Best Pract Res Clin Gastroenterol 2013; 27:127-137
68. Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013; 500:232-236
69. Chandrasekharan D, Issa F, Wood KJ. Achieving operational tolerance in transplantation: How can lessons from the clinic inform research directions? Transpl Int 2013; 26:576-589
70. Londonö MC, Danger R, Giral M, et al. A need for biomarkers of operational tolerance in liver and kidney transplantation. Am J Transplant 2012; 12:1370-1377
71. Benítez C, Londoño MC, Miquel R, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 2013. doi: 10.1002/hep.26426. [Epub ahead of print]
72. Bohne F, Martínez-Llordella M, Lozano JJ, et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest 2012; 122:368-382
73. Lozano JJ, Pallier A, Martinez-Llordella M, et al. Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients. Am J Transplant 2011; 11:1916-1926
74. Cobbold SP, Adams E, Waldmann H. Biomarkers of transplantation tolerance: More hopeful than helpful? Front Immunol 2011; 2:9